Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 5Parasomnias 3Neoplasms 3Tuberous Sclerosis 2Smith-Magenis Syndrome 2Lung Neoplasms 2Autism Spectrum Disorder 2Angelman Syndrome 2Weight Loss 1Squamous Cell Carcinoma of Head and Neck 1Sleep Wake Disorders 1Sleep Disorders, Circadian Rhythm 1Relapsed Malignant Solid Tumor 1Radiodermatitis 1Radiation Injuries 1Polycystic Ovary Syndrome 1Pain 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fatigue 1Depression 1Delirium 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Brain Neoplasms 1Barrett Esophagus 1Anorexia 1

Interventions

Haloperidol 2Vitamin E 1Surveys and Questionnaires 1Sodium Chloride 1Sevoflurane 1Propofol 1Pemetrexed 1Paclitaxel 1Olanzapine 1Neoadjuvant Therapy 1Mental Status and Dementia Tests 1Melatonin 1Injections 1Inhalation 1Donepezil 1Dexmedetomidine 1Anesthesia, Spinal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Delirium × Melatonin × Clear all
NCT02200172 2016-07-19

The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study

Bruyère Health Research Institute.

Phase 2 Completed
60 enrolled

Delirium, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡